We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

One for all

6 October 2016 By Robert Cyran

Half Alnylam’s market value evaporated after patient deaths ended a drug trial. The promise of novel treatments based on RNA interference had pushed its market value to $12 bln. That’s now down to $3 bln, suggesting investors fear trouble with one may indicate problems with all.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)